Skip to main content

Table 1 Baseline characteristics of patients who did not complete the therapy and those who completed it

From: Extent of liver inflammation in predicting response to interferon α & Ribavirin in chronic hepatitis C patients: a cohort study

Study variable

Did not complete treatment

Completed treatment

P-value

 

nL

Response to variable

nC

Response to variable

 

Age: n (%)

120

 

876

  

< 40 year

 

79 (65.8)

 

534 (61.0)

0.31a

≥ 40 year

 

41 (34.2)

 

342 (39.0)

 

Gender: n (%)

120

 

876

 

0.20a

Male

 

65 (54.2)

 

417 (47.6)

 

Female

 

55 (45.8)

 

459 (52.4)

 

Marital Status: n (%)

120

 

876

 

0.46a

Single

 

18(15.0)

 

107(12.2)

 

Married

 

102(85.0)

 

769(87.8)

 

HCV genotype n (%)

10

 

91

 

0.85 b

Genotype 1

 

0 (0)

 

1 (1.1)

 

Genotype 2

 

1 (10)

 

3 (3.3)

 

Genotype 3

 

9 (90.0)

 

86 (94.5)

 

Genotype 4

 

0 (0)

 

1 (1.1)

 

Viral load in IU/mL(median(IQR))

16

594,217(16,481–29,445,155)

125

508,551(493–79,121,294)

0.30 c

ALT in U/L(median(IQR))

108

79.5(16–957)

796

72(11–781)

0.45c

AST in U/L (median(IQR))

21

69(23–230)

151

46(14–508)

0.03c

Bilirubin in mg/dL(mean ± SD)

82

0.99 ± 0.44

553

0.89 ± 0.40

0.05d

Alkaline Phosphatase in U/L (mean ± SD)

82

218.8 ± 77.8

535

207.4 ± 98.7

0.31d

Albumin in g/dL (mean ± SD)

23

4.3 ± 0.4

170

4.2 ± 0.6

0.32d

Alpha Fetoprotein in ng/mL (median(IQR))

6

2.18(0.5–10.4)

63

2.4(0.2–16.5)

0.85c

Hb in g/dL (mean ± SD)

116

15.4 ± 14.2

826

13.7 ± 5.07

0.01d

TLC in cell × 10 9 /L(mean ± SD)

114

8.7 ± 8.8

805

7.5 ± 2.6

0.002d

  1. a-Chi-square test, b-Fisher’s exact test, c-Mann Whitney-U test, d-Student’s t-test; n L : no. of patients who did not complete treatment, n C : no. of patients who completed treatment.